Sign up
Healthed-White-on-Blue
Thomas, Merlin_V2

Prof Merlin Thomas

Clinician Scientist; Program Leader, Department of Diabetes, Monash University
Professor Merlin Thomas is a clinician scientist and program leader in the Department of Diabetes at Monash University. He is also a Fellow of the Australian Academy of Medicine Science and Founder of RAGE Biotech. His research program is focused on understanding the mechanisms of diabetic complications and developing new opportunities for their prevention and treatment.

More from this expert

pexels-pixabay-356175
Podcasts iconPodcasts

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

shutterstock_1971285998
Podcasts iconPodcasts

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Feature

Controlling Glucose in Patients with Renal Impairment

This article discusses common co-morbidities of type 2 diabetes and poor kidney function, and how optimal management must account for the mutual effects of one condition on the other.

By Prof Merlin Thomas
Monographs iconMonographs
Feature

Managing Diabetes in Patients with Liver Disease

This article discusses how to assess abnormal liver function in a patient with type 2 diabetes, and the importance of managing this condition to improve long-term health outcomes.

By Prof Merlin Thomas
Monographs iconMonographs
Feature

Diabetes in the Older Adult

This article discusses the complications and considerations associated with managing older patients with type 2 diabetes and the need for an individualised approach.

By Prof Merlin Thomas
Monographs iconMonographs
MT5 Feature

Combining SGLT2 and DPP-4 Inhibition in Type 2 Diabetes

This article discusses the evidence for using a combination of SGLT2 inhibitors & DPP-4 inhibitors in addition to standard care for the management of type 2 diabetes and its complications.

By Prof Merlin Thomas
Monographs iconMonographs
Banner

DPP-4 Inhibition: Playing the Long Game in Type 2 Diabetes

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

By Prof Merlin Thomas
Monographs iconMonographs
Banner

DPP-4 Inhibitors: Similarities and Differences

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

By Prof Merlin Thomas
Monographs iconMonographs
Merlin snip

SGLT2 and DPP4 Inhibition: An Ideal Combination

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

By Prof Merlin Thomas
Monographs iconMonographs
shutterstock_1971285998

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

By Prof Merlin Thomas
Podcasts iconPodcasts
pexels-pixabay-356175

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

By Prof Merlin Thomas
Podcasts iconPodcasts

Education by clinicians, for clinicians

Get the app

Site

Company

Connect

Legal

Discover

Healthed

CPD platform

Upcoming Healthed Webcast

Importance of Early & Effective Treatment of Mild to Moderate Acne

Tuesday 11th November, 7pm - 9pm AEDT

Speaker

Dr Ryan De Cruz

Specialist Dermatologist

We invite you to our next free webcast, where I will discuss the importance of early and effective treatment of mild to moderate acne. Earn up to 4 hours CPD. RACGP & ACRRM accredited.

Register for this webcast